Sign In
Get Clay Free →

Suggestions

    Michael Muelly

    Making machine intelligence for healthcare work

    Michael C. Muelly, M.D., is the Co-founder and Chief Technology Officer (CTO) at IMVARIA Inc., a health tech company that develops AI-driven digital biomarker solutions.126 These solutions aim to help healthcare professionals make more accurate diagnoses and improve patient outcomes.1 IMVARIA was founded in 2019 by physician-engineers from Google and Stanford University.34 The company's Digital Biomarker Lab uses automated, machine-learning algorithm technology to transform clinical decision-making into data science.34

    Muelly's background and roles:

    • Education: He earned a Doctor of Medicine (MD) from Penn State University and studied Engineering Physics/Neural Engineering (though his PhD is incomplete).6 He completed a Residency in General Surgery at Penn State College of Medicine, followed by a Residency in Diagnostic Radiology and a Fellowship in Body MR Imaging at Stanford University.6 Muelly also holds a Bachelor of Science (B.S.) in Mathematics and Computer Science from the University of Pittsburgh and an Associate of Science (A.S.) in Accounting from the Community College of Allegheny County.6 He is certified in Diagnostic Radiology by the American Board of Radiology.6
    • Experience: Before co-founding IMVARIA, Muelly was a Product Manager and Machine Learning Researcher at Google.1 He also has experience as a Clinical Assistant Professor of Radiology at Stanford University and as an Emergency Radiologist for Vision Radiology.6 Muelly's prior roles include Chief Medical Officer of GYANT, Healthcare AI Consultant at Dignity Health, and founder of ClariPACS LLC and Intradetect.6

    Muelly's work at IMVARIA focuses on applying machine intelligence to data from sources like imaging or wearables to develop digital biomarkers.1 These biomarkers help healthcare professionals in the diagnosis of severe and rare diseases.1 IMVARIA's headquarters are in Berkeley, CA.34

    IMVARIA has achieved significant milestones, including FDA authorization for its Fibresolve digital biomarker solution, which aids in the non-invasive diagnosis of lung fibrosis.45 In January 2025, IMVARIA received 510(k) clearance from the FDA for its ScreenDx solution, an AI-powered tool that assists clinicians in assessing for interstitial lung disease (ILD).7

    Highlights

    Jan 13 · businesswire.com
    IMVARIA Receives 510(k) Clearance for ScreenDx, a First-of-its ...
    Nov 18 · theorg.com
    Michael C. Muelly, M.D. - Founder & CTO at imvaria | The Org
    Michael Muelly, MD - UCSF Rosenman Institute
    May 24 · imvaria.com
    Fibresolve | The first FDA-authorized AI diagnostic tool in IPF - Imvaria
    May 18 · biospace.com
    IMVARIA Announces Data Demonstrating Company's Non-Invasive ...
    Oct 6 · imvaria.com
    Imvaria
    Imvaria
    Feb 18 · Radiology Business
    Big-name technology company leaders urge radiologists to 'Ditch the Disk' - Radiology Business
    Feb 16 · CNBC
    'Ditch the Disk' group of tech execs is spurring the medical industry to move on from CD-ROMs - CNBC

    Related Questions

    What are digital biomarkers and how do they improve healthcare?
    How did Michael Muelly transition from being a radiologist to a tech entrepreneur?
    What are some of the key projects Michael Muelly has worked on at imvaria?
    How does imvaria's collaboration with Mayo Clinic benefit cancer research?
    What is the significance of imvaria's FDA authorization for Fibresolve?
    Michael Muelly
    Michael Muelly, photo 1
    Michael Muelly, photo 2
    Add to my network

    Location

    Mountain View, California, United States